Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 12/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21828450 | 0.75 | LCK (0.36) | GNRHRPOLBCASP3 | |
| SCHEMBL18919411 | 0.68 | HEXA (0.44) | MAPT | |
| SCHEMBL18919446 | 0.67 | SMN1; SMN2 (0.47) | POLBALDH1A1CASP3 | |
| SCHEMBL30753531 | 0.67 | SMN1; SMN2 (0.47) | POLBALDH1A1CASP3 | |
| SCHEMBL18919421 | 0.66 | GAA (0.41) | POLBARCASP3 | |
| SCHEMBL15571328 | 0.65 | ALDH1A1 (0.43) | MAPTALDH1A1 | |
| SCHEMBL16685122 | 0.65 | ALDH1A1 (0.47) | MAPTPOLBALDH1A1 | |
| SCHEMBL18942729 | 0.64 | AKT1 (0.49) | — | |
| SCHEMBL21909057 | 0.64 | HEXA (0.47) | — | |
| SCHEMBL21909067 | 0.63 | CDK8 (0.36) | MAPTALDH1A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383846-B1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | OTAGO INNOVATION LTD (NZ) | 2022-06-22 | — | — | EP | disclosed |
| US-11072584-B2 | Carbon monoxide releasing norbornenone compounds | OTAGO INNOVATION LIMITED (NZ) | 2021-07-27 | — | — | US | disclosed |
| US-20200109115-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109115-A1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | HMOX1, MB, NOS2 | GNRHR 3788/4885MAPT 4693/4885POLB 4692/4885 |
| US-11072584-B2 | Carbon monoxide releasing norbornenone compounds | HMOX1, MB, NOS2 | GNRHR 3788/4885MAPT 4693/4885POLB 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.